FOLD vs. BHVN, ARWR, BHC, PRGO, TPTX, RGEN, EXAS, EXEL, HALO, and IONS
Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Biohaven (BHVN), Arrowhead Pharmaceuticals (ARWR), Bausch Health Companies (BHC), Perrigo (PRGO), Turning Point Therapeutics (TPTX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector.
Biohaven (NYSE:BHVN) and Amicus Therapeutics (NASDAQ:FOLD) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, profitability, risk and institutional ownership.
Biohaven has a net margin of 0.00% compared to Biohaven's net margin of -34.73%. Biohaven's return on equity of -77.08% beat Amicus Therapeutics' return on equity.
Biohaven has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
88.8% of Biohaven shares are owned by institutional investors. 16.0% of Biohaven shares are owned by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Amicus Therapeutics received 144 more outperform votes than Biohaven when rated by MarketBeat users. Likewise, 73.54% of users gave Amicus Therapeutics an outperform vote while only 65.55% of users gave Biohaven an outperform vote.
Amicus Therapeutics has lower revenue, but higher earnings than Biohaven. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
In the previous week, Amicus Therapeutics had 8 more articles in the media than Biohaven. MarketBeat recorded 13 mentions for Amicus Therapeutics and 5 mentions for Biohaven. Amicus Therapeutics' average media sentiment score of 1.39 beat Biohaven's score of 0.60 indicating that Biohaven is being referred to more favorably in the media.
Biohaven currently has a consensus target price of $55.00, suggesting a potential upside of 63.50%. Amicus Therapeutics has a consensus target price of $17.57, suggesting a potential upside of 74.84%. Given Biohaven's higher possible upside, analysts clearly believe Amicus Therapeutics is more favorable than Biohaven.
Summary
Biohaven and Amicus Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Amicus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amicus Therapeutics Competitors List
Related Companies and Tools
